Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support development of Lucid-21-302, the company's patented investigational drug designed to inhibit demyelination in MS. Dr. Antel, a recipient of the National Multiple Sclerosis Society and American Academy of Neurology's Dystel Award with over 450 published articles, will guide the design of efficacy trials as Quantum advances Lucid-MS into Phase 2 studies.
The appointment of such a distinguished MS specialist signals Quantum BioPharma's serious commitment to advancing treatment for multiple sclerosis, a chronic autoimmune disease affecting approximately 2.8 million people worldwide. Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor, creating a formidable team of neurological experts to shepherd the drug through clinical development.
Lucid-MS represents a novel approach to MS treatment as a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation constitutes the underlying mechanism of multiple sclerosis, where the immune system attacks the protective covering of nerve fibers, causing communication problems between the brain and the rest of the body. Current treatments primarily focus on managing symptoms and reducing relapse rates, but few address the fundamental demyelination process.
This development matters because multiple sclerosis patients face limited treatment options that directly target the core pathology of the disease. If successful, Lucid-MS could potentially offer a disease-modifying therapy that goes beyond symptom management to actually repair the neurological damage characteristic of MS. The progression to Phase 2 studies represents a critical milestone in determining whether the promising preclinical results translate to human patients.
Quantum BioPharma maintains additional business interests through its strategic investments and retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025. The company also holds rights to develop similar products for pharmaceutical and medical uses. Investors can access the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM. The full press release detailing Dr. Antel's appointment is available at https://ibn.fm/NWMFj.
The involvement of internationally recognized MS experts like Dr. Antel provides credibility to Quantum BioPharma's research program and increases the likelihood of developing an effective treatment. For the millions living with MS worldwide, this represents potential hope for a therapy that addresses the fundamental neurological damage rather than merely managing symptoms. The biopharmaceutical industry closely watches such developments as successful neuroprotective treatments could establish new standards for neurodegenerative disease management.
